Stock THER THERALINK TECHNOLOGIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Theralink Technologies, Inc.

Equities

THER

US88339Q1094

Delayed OTC Markets
Other stock markets
 08:12:37 20/05/2024 pm IST 		5-day change 1st Jan Change
0.0007 USD 0.00% Intraday chart for Theralink Technologies, Inc. 0.00% -53.33%
06/05 Theralink Technologies, Inc. cancelled the acquisition of IMAC Holdings, Inc. in a reverse merger transaction. CI
20/02 Theralink Technologies, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Theralink Technologies : Accelaration/Increase of Financial Obligation - Form 8-K
PU
Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates
AQ
Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4
AQ
Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board
AQ
Four Penny Stocks That Might Move On News (EPAZ, THER, SDNR, HNRC)
AQ
Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023
AQ
Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer
AQ
Theralink Acquires Exclusive Landmark Immunotherapy Patent including Biomarker from Vanderbilt University
AQ
Theralink® Acquires Exclusive Landmark Immunotherapy Patent including Biomarker from Vanderbilt University
PR
Theralink® Technologies Begins Receiving Payments from Third Party Payors for its Advanced Breast Cancer Assay, Achieving Key Milestone
PR
THERALINK TECHNOLOGIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
THERALINK TECHNOLOGIES, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)
AQ
Theralink's Exclusive Licensed RPPA Technology for Commercial Laboratory Testing to Assist the White House Cancer Moonshot Initiative
PR
Theralink® Technologies Appoints Michael Vallone as Senior Director of Commercialization
PR
THERALINK TECHNOLOGIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
THERALINK TECHNOLOGIES, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
THERALINK TECHNOLOGIES, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Theralink® Technologies Accepted to Present Two Posters at the Upcoming San Antonio Breast Cancer Symposium
PR
Theralink® Technologies Announces Closing of Private Placement and Conversion of Existing Convertible Notes and Convertible Preferred Shares
PR
Theralink® Technologies Receives Final Medicare Reimbursement Rate Determination and PTAN Enrollment
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. THER Stock
  4. News Theralink Technologies, Inc.
  5. Press Releases